ARTICLE | Clinical News
GS 504: Completed interim analysis of its Phase II/III trial
June 20, 1994 7:00 AM UTC
Gilead Sciences Inc. (GILD), Foster City, Calif. Product: GS 504, nucleotide analog Indication: Retinitis caused by cytomegalovirus infection in AIDS Status: Completed interim analysis of its Phase I...